Celldex Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Celldex Therapeutics' es Anthony Marucci , nombrado en May 2003, tiene una permanencia de 20.92 años. compensación anual total es $5.40M, compuesta por 12.8% salario y 87.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.044% de las acciones de la empresa, por valor de €1.02M. La antigüedad media del equipo directivo y de la junta directiva es de 6.8 años y 11.2 años, respectivamente.

Información clave

Anthony Marucci

Chief Executive Officer (CEO)

US$8.4m

Compensación total

Porcentaje del salario del CEO	8.6%
Permanencia del CEO	21yrs
Participación del CEO	0.04%
Permanencia media de la dirección	7.9yrs
Promedio de permanencia en la Junta Directiva	11.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Anthony Marucci en comparación con los beneficios de Celldex Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$8m	US$721k	-US$141m
Sep 30 2023	n/a	n/a	-US$125m
Jun 30 2023	n/a	n/a	-US$113m
Mar 31 2023	n/a	n/a	-US$119m
Dec 31 2022	US$5m	US$693k	-US$112m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$100m
Mar 31 2022	n/a	n/a	-US$77m
Dec 31 2021	US$6m	US$669k	-US$71m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$66m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$3m	US$644k	-US$60m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$46m
Dec 31 2019	US$1m	US$619k	-US$51m
Sep 30 2019	n/a	n/a	-US$50m
Jun 30 2019	n/a	n/a	-US$46m
Mar 31 2019	n/a	n/a	-US$50m
Dec 31 2018	US$1m	US$608k	-US$151m
Sep 30 2018	n/a	n/a	-US$146m
Jun 30 2018	n/a	n/a	-US$165m
Mar 31 2018	n/a	n/a	-US$177m
Dec 31 2017	US$2m	US$598k	-US$93m

Compensación vs. Mercado: La compensación total de Anthony($USD5.40M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD2.37M).

Compensación vs. Ingresos: La compensación de Anthony ha aumentado mientras la empresa no es rentable.

CEO

Anthony Marucci (61 yo)

21yrs

Permanencia

US$8,361,844

Compensación

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Anthony Marucci	Founder	21yrs	US$8.36m	0.043% $ 1.1m
Tibor Keler	Founder	21yrs	US$3.42m	0.011% $ 290.8k
Sam Martin	Senior VP	6.8yrs	US$2.95m	0.053% $ 1.4m
Margo Heath-Chiozzi	Senior Vice President of Regulatory Affairs	6.6yrs	US$2.94m	0.018% $ 478.1k
Diane Young	Senior VP & Chief Medical Officer	4.9yrs	US$2.97m	0.071% $ 1.9m
Joseph Schlessinger	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration	6.9yrs	sin datos	0.0019% $ 50.8k
Freddy Jimenez	Senior VP & General Counsel	3.3yrs	US$2.17m	0.039% $ 1.0m
Ronald Pepin	Chief Business Officer & Senior VP	12.8yrs	US$1.88m	sin datos
Elizabeth Crowley	Chief Product Development Officer & Senior VP	9.8yrs	US$1.18m	sin datos
Richard Wright	Chief Commercial Officer & Senior VP	8.8yrs	US$563.17k	0.00032% $ 8.3k

7.9yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TCE2 es experimentado (6.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Anthony Marucci	Founder	15.4yrs	US$8.36m	0.043% $ 1.1m
Joseph Schlessinger	Co-Founder & Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos
Harry Penner	Independent Director	27.3yrs	US$371.19k	0.0042% $ 110.2k
Herbert Conrad	Independent Director	16.2yrs	US$364.94k	0.0039% $ 101.4k
Louis Weiner	Member of Scientific Advisory Board	no data	sin datos	sin datos
James Marino	Independent Director	7.2yrs	US$377.44k	0.019% $ 502.1k
Karen Shoos	Independent Chair of the Board of Directors	23yrs	US$385.77k	0.0042% $ 110.2k
Carl June	Member of Scientific Advisory Board	no data	sin datos	sin datos
Michel Nussenzweig	Member of Scientific Advisory Board	no data	sin datos	sin datos
Marc Rothenberg	Member of Scientific Advisory Board	no data	sin datos	sin datos
Keith Brownlie	Independent Director	6.9yrs	US$373.27k	0.0010% $ 26.3k
Cheryl Cohen	Independent Director	1.9yrs	US$367.02k	0% $ 0

11.3yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de TCE2 son experimentados ( 11.2 años antigüedad media).

Celldex Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics, Inc. Announces Board Appointments

Insufficient new directors

Celldex Therapeutics, Inc. Promotes Freddy Jimenez, to the Newly Created Position of Senior Vice President and General Counsel

Recent updates

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings released: US$2.92 loss per share (vs US$2.40 loss in FY 2022)

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2022)

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.77 loss in 2Q 2022)

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Now 22% undervalued after recent price drop

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.49 loss in 1Q 2022)

Full year 2022 earnings released: US$2.40 loss per share (vs US$1.65 loss in FY 2021)

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Second quarter 2022 earnings released: US$0.77 loss per share (vs US$0.34 loss in 2Q 2021)

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces Board Appointments

First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.36 loss in 3Q 2020)

Celldex Therapeutics, Inc. Announces Initiation of CDX-0159 Subcutaneous Formulation Study

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.50 loss in 2Q 2020)

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial

Celldex Therapeutics, Inc. Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

First quarter 2021 earnings released: US$0.42 loss per share (vs US$0.72 loss in 1Q 2020)

Celldex Provides Reports Impairment for the Fourth Quarter of 2020

Full year 2020 earnings released: US$2.02 loss per share (vs US$3.51 loss in FY 2019)

New 90-day high: €24.00

Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)

New 90-day high: €20.00

Celldex Therapeutics, Inc. Promotes Freddy Jimenez, to the Newly Created Position of Senior Vice President and General Counsel

Celldex Therapeutics, Inc. Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

New 90-day high: €19.13

Celldex Therapeutics, Inc. Initiates Phase 1B Study of Cdx-0159 in Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad